Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.79 |
| ▸ | RAB9A | P51151 | 1/20 | 0.79 |
| ▸ | LTA4H | P09960 | 2/20 | 0.77 |
| ▸ | TSHR | P16473 | 3/20 | 0.69 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.63 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | CA12 | O43570 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | CA7 | P43166 | 1/20 | 0.61 |
| ▸ | CA9 | Q16790 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | SCN1A | P35498 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14204567 | 0.98 | NPC1 (0.77) | NPC1RAB9ALTA4HTSHRPSMB1 | |
| Hydrochloric Acid SCHEMBL7013705 | 0.98 | NPC1 (0.82) | NPC1RAB9ALTA4HTSHRPSMB1 | |
| SCHEMBL7006505 | 0.91 | MAPK1 (0.73) | NPC1RAB9ALTA4HTSHRKDM4E | |
| SCHEMBL7008655 | 0.90 | TSHR (0.76) | NPC1RAB9ALTA4HTSHRKDM4E | |
| SCHEMBL11898739 | 0.90 | NPC1 (0.97) | NPC1RAB9ALTA4HPSMB1PSMB5 | |
| SCHEMBL12128299 | 0.88 | ALDH1A1 (0.70) | TSHRKDM4EALDH1A1 | |
| SCHEMBL7138464 | 0.88 | LTA4H (1.00) | NPC1RAB9ALTA4HPSMB1PSMB5 | |
| SCHEMBL1956688 | 0.88 | LTA4H (0.79) | NPC1RAB9ALTA4HKDM4E | |
| SCHEMBL14578276 | 0.86 | ALDH1A1 (0.69) | NPC1RAB9ALTA4HTSHRKDM4E | |
| SCHEMBL12108094 | 0.86 | NPC1 (0.70) | NPC1RAB9ALTA4HTSHRPSMB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1594857-A2 | N-MONOACYLATED O-PHENYLENEDIAMINES AS ANTI-CANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-16 | — | — | EP | claimed |
| WO-2004069133-A2 | N-MONOACYLATED O-PHENYLENEDIAMINES AS ANTI -CANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-19 | — | — | WO | claimed |
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| EP-3498701-B1 | PRMT5 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2023-02-22 | — | — | EP | disclosed |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-3441392-B1 | A PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | INTELLIKINE LLC (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-2870156-B1 | PYRIMIDINONE DERIVATIVES AS ANTIMALARIAL AGENTS | SANOFI SA (FR) | 2020-06-17 | — | — | EP | disclosed |
| US-10301267-B2 | Compounds | ASTRAZENECA AB (SE) | 2019-05-28 | — | — | US | disclosed |
| EP-3441392-A1 | A PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | Intellikine, LLC (US) | 2019-02-13 | — | — | EP | disclosed |
| US-20170313701-A1 | Fused Heterocyclic Compounds as Selective BMP Inhibitors | VANDERBILT UNIVERSITY | 2017-11-02 | — | — | US | disclosed |
| WO-2007038669-A9 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC | 2008-05-29 | — | — | WO | disclosed |
| US-7183409-B2 | Basic mono- and bisazo compounds | CLARIANT FINANCE (BVI) LIMITED (VG) | 2007-02-27 | — | — | US | disclosed |
| US-7183409-B2 | Basic mono- and bisazo compounds | CLARIANT FINANCE (BVI) LIMITED (VG) | 2007-02-27 | — | — | US | disclosed |
| US-6559167-B1 | Prodrugs of the pyridyl methyl sulfinyl benzimidazole type proton pump inhibitor drugs have a hydrolyzable arylsulfonyl or heteroarylsulfonyl group attached to the benzimidazole nitrogen. The prodrugs of the invention hydrolyze under | REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-05-06 | — | — | US | disclosed |
| EP-1289985-A2 | BETA-CARBOLINE DERIVATIVES USEFUL AS INHIBITORS OF PHOSPHODIESTERASE | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-03-12 | — | — | EP | disclosed |
| EP-1105387-B1 | PRODRUGS OF PROTON PUMP INHIBITORS | WINSTON PHARMATEUTICALS LLC (US) | 2003-01-29 | — | — | EP | disclosed |
| EP-1240148-A1 | BENZO[A]PHENAZIN-11-CARBOXAMIDE DERIVATIVES AND THEIR USE AS JOINT INHIBITORS OF TOPOMERASE I AND II | Xenova Limited (GB) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001087038-A2 | β-CARBOLINE DERIVATIVES USEFUL AS INHIBITORS OF PHOSPHODIESTERASE | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-11-22 | — | — | WO | disclosed |
| WO-2001046157-A1 | BENZO[A]PHENAZIN-11-CARBOXAMIDE DERIVATIVES AND THEIR USE AS JOINT INHIBITORS OF TOPOMERASE I AND II | XENOVA LIMITED (GB) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301267-B2 | Compounds | SLC10A1, CYP11B1, ABCB11 | NPC1 52/4885RAB9A 1091/4885LTA4H 3661/4885 |
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NNT | NPC1 161/4885RAB9A 1657/4885LTA4H 2871/4885 |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | NPC1 174/4885RAB9A 1917/4885LTA4H 2984/4885 |
| US-20170313701-A1 | Fused Heterocyclic Compounds as Selective BMP Inhibitors | BMP1, BMP4, BMP2 | NPC1 3037/4885RAB9A 1421/4885LTA4H 3552/4885 |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | NPC1 123/4885RAB9A 1445/4885LTA4H 2761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.